Indication:Metastatic melanoma with a BRAF V600 mutation
Non-small cell lung cancer with a BRAF V600 mutation.
Stage III Melanoma with a BRAF V600 mutation, following complete resection.
Drug Safety Update March 2016
Risk of gastrointestinal perforation and colitis: